je.st
news
FDA Approves New U.S. Labeling for ISENTRESS (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients
2013-07-01 23:05:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved new labeling for ISENTRESS (raltegravir) Film-coated Tablets, Mercks integrase inhibitor for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy. Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Claire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
include
study
adult
Category:Biotechnology and Pharmaceuticals